Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Arch Virol

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    July 2024
  1. LIU C, Li S, Qiao M, Zeng C, et al
    GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection.
    Arch Virol. 2024;169:167.
    PubMed     Abstract available

  2. LUO J, Zhang M, Ye Q, Gao F, et al
    A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice.
    Arch Virol. 2024;169:163.
    PubMed     Abstract available

    April 2024
  3. ALVAREZ-QUINTO R, Grinstead S, Kinard G, Martin R, et al
    Complete genome sequence of vaccinium-associated virus C, a new member of the family Totiviridae from Vaccinium floribundum.
    Arch Virol. 2024;169:86.
    PubMed     Abstract available

    March 2024
  4. LATIFI T, Kachooei A, Jalilvand S, Zafarian S, et al
    Correlates of immune protection against human rotaviruses: natural infection and vaccination.
    Arch Virol. 2024;169:72.
    PubMed     Abstract available

    February 2024
  5. TAFFAREL AI, Barrios Benito MY, Hung VV, Cardillo S, et al
    Foot-and-mouth disease virus strains isolated in Vietnam during 2010-2019: genetic characterization and antigenic relatedness to the Euro SA vaccine.
    Arch Virol. 2024;169:44.
    PubMed     Abstract available

    January 2024
  6. SPRYGIN A, van Schalkwyk A, Mazloum A, Byadovskaya O, et al
    Genome sequence characterization of the unique recombinant vaccine-like lumpy skin disease virus strain Kurgan/2018.
    Arch Virol. 2024;169:23.
    PubMed     Abstract available

  7. MACEDO LFR, Ribeiro EC, Wanzala EJ, Neto OCS, et al
    Pentavalent and poliomyelitis vaccines: a review of the vaccination coverage in Brazilian children in the last 10 years.
    Arch Virol. 2024;169:17.
    PubMed     Abstract available

    November 2023
  8. ABDUL-KAREEM HH, Al-Maqtoofi MY, Burghal AA
    Impact of COVID-19 vaccination on saliva immune barriers: IgA, lysozyme, and lactoferrin.
    Arch Virol. 2023;168:293.
    PubMed     Abstract available

    September 2023
  9. MESEKO C, Ameji NO, Kumar B, Culhane M, et al
    Rational approach to vaccination against highly pathogenic avian influenza in Nigeria: a scientific perspective and global best practice.
    Arch Virol. 2023;168:263.
    PubMed     Abstract available

    August 2023
  10. GNEZDILOVA LA, Laga VY, Marzanova SN, Pozyabin SV, et al
    Evidence of insufficient genetic data and lack of regular genetic research on rabies virus in the Russian Federation: a study of the recent epizootic situation.
    Arch Virol. 2023;168:219.
    PubMed     Abstract available

    July 2023
  11. REN X, Zeng Z, Shang Y, Yao L, et al
    C-terminal truncation of the hemagglutinin-neuraminidase (HN) protein enhances the virulence and immunogenicity of Newcastle disease virus (NDV) vaccine strain V4.
    Arch Virol. 2023;168:203.
    PubMed     Abstract available

  12. LENG M, Bian X, Chen Y, Liang Z, et al
    The attenuated live vaccine strain W2512 provides protection against novel variant infectious bursal disease virus.
    Arch Virol. 2023;168:200.
    PubMed     Abstract available

    June 2023
  13. BHANOTHU V, Munne K, Pande S, Singh P, et al
    The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021.
    Arch Virol. 2023;168:188.
    PubMed     Abstract available

  14. GWYNN A, Mbewana S, Lubisi BA, Tshabalala HM, et al
    Chimaeric plant-produced bluetongue virus particles as potential vaccine candidates.
    Arch Virol. 2023;168:179.
    PubMed     Abstract available

  15. AMIT LN, John JL, Mori D, Chin AZ, et al
    Increase in rotavirus prevalence with the emergence of genotype G9P[8] in replacement of genotype G12P[6] in Sabah, Malaysia.
    Arch Virol. 2023;168:173.
    PubMed     Abstract available

    May 2023
  16. ZHANG Y, Wang J, Xie Y, Cao X, et al
    Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China.
    Arch Virol. 2023;168:164.
    PubMed     Abstract available

    April 2023
  17. TUSHABE P, Bwogi J, Eliku JP, Aine F, et al
    Environmental surveillance detects circulating vaccine-derived poliovirus type 2 that was undetected by acute flaccid paralysis surveillance in 2021 in Uganda.
    Arch Virol. 2023;168:140.
    PubMed     Abstract available

    March 2023
  18. MARTINS M, do Nascimento GM, Conforti A, Noll JCG, et al
    A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
    Arch Virol. 2023;168:124.
    PubMed     Abstract available

    February 2023
  19. NEMOTO M, Reedy SE, Yano T, Suzuki K, et al
    Antigenic comparison of H3N8 equine influenza viruses belonging to Florida sublineage clade 1 between vaccine strains and North American strains isolated in 2021-2022.
    Arch Virol. 2023;168:94.
    PubMed     Abstract available

    January 2023
  20. BAZID AH, Amer HM, Nayel M, Attia M, et al
    Assessment of the potency and effectiveness of a heptavalent oil-adjuvanted (ISA 206) foot-and-mouth disease vaccine in Egypt.
    Arch Virol. 2023;168:62.
    PubMed     Abstract available

  21. HUANG Y, Xu H, Liu S, Lu J, et al
    Accidental acquisition of a rescued Japanese encephalitis virus with unspliced introns in the viral genome when using an intron-based stabilization approach.
    Arch Virol. 2023;168:60.
    PubMed     Abstract available

  22. KATSURA M, Fukushima M, Kameyama KI, Kokuho T, et al
    Novel bovine viral diarrhea virus (BVDV) virus-like particle vaccine candidates presenting the E2 protein using the SpyTag/SpyCatcher system induce a robust neutralizing antibody response in mice.
    Arch Virol. 2023;168:49.
    PubMed     Abstract available

  23. BANNAI H, Kambayashi Y, Nemoto M, Ohta M, et al
    Experimental challenge of horses after prime-boost immunization with a modified live equid alphaherpesvirus 1 vaccine administered by two different routes.
    Arch Virol. 2023;168:27.
    PubMed     Abstract available

    November 2022
  24. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    PubMed     Abstract available

    September 2022
  25. LI ZX, Feng S, Zhang H, Zhuang XY, et al
    Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
    Arch Virol. 2022 Sep 9. pii: 10.1007/s00705-022-05562.
    PubMed     Abstract available

  26. PONNUSAMY P, Sukumar K, Raja A, Saravanan S, et al
    Characterization of infectious laryngotracheitis virus isolates from laying hens during 2019-2020 outbreaks in Tamil Nadu, India.
    Arch Virol. 2022;167:1819-1829.
    PubMed     Abstract available

    July 2022
  27. JUNG JS, Lee R, Yoon SI, Lee GS, et al
    Genetic and immunological characterization of commercial infectious bronchitis virus vaccines used in Korea.
    Arch Virol. 2022 Jul 11. pii: 10.1007/s00705-022-05519.
    PubMed     Abstract available

  28. DOAN HTT, Do RT, Thao PTP, Le XTK, et al
    Molecular genotypic analysis of porcine circovirus type 2 reveals the predominance of PCV2d in Vietnam (2018-2020) and the association between PCV2h, the recombinant forms, and Vietnamese vaccines.
    Arch Virol. 2022 Jul 6. pii: 10.1007/s00705-022-05517.
    PubMed     Abstract available

    June 2022
  29. BHANUPRAKASH V, Hosamani M, Venkatesan G, Singh RK, et al
    Long-term protective immunity to goatpox in goats after a single immunization with a live attenuated goatpox vaccine.
    Arch Virol. 2022 Jun 26. pii: 10.1007/s00705-022-05505.
    PubMed     Abstract available

  30. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
    COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
    PubMed     Abstract available

    May 2022
  31. PIERI M, Nicolai E, Nuccetelli M, Sarubbi S, et al
    Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Arch Virol. 2022;167:1285-1291.
    PubMed     Abstract available

    April 2022
  32. BIN UMAIR M, Akusa FN, Kashif H, Seerat-E-Fatima, et al
    Viruses as tools in gene therapy, vaccine development, and cancer treatment.
    Arch Virol. 2022 Apr 24. pii: 10.1007/s00705-022-05432.
    PubMed     Abstract available

    February 2022
  33. OZ ME, Torlak E
    A high-resolution melting assay to differentiate a peste des petits ruminants virus vaccine strain from field isolates in Turkey.
    Arch Virol. 2022 Feb 11. pii: 10.1007/s00705-022-05386.
    PubMed     Abstract available

  34. ZHOU J, Li C, Tang A, Li H, et al
    Immunogenicity of an inactivated novel goose parvovirus vaccine for short beak and dwarfism syndrome in Cherry Valley ducks.
    Arch Virol. 2022 Feb 11. pii: 10.1007/s00705-021-05352.
    PubMed     Abstract available

  35. LI H, Ge Z, Luo Q, Fu Q, et al
    A highly pathogenic Marek's disease virus isolate from chickens immunized with a bivalent vaccine in China.
    Arch Virol. 2022 Feb 7. pii: 10.1007/s00705-021-05355.
    PubMed     Abstract available

    January 2022
  36. COKCALISKAN C, Tuncer-Goktuna P, Sareyyupoglu B, Turkoglu T, et al
    Booster administration can make a difference in the antibody response to intradermal foot-and-mouth disease vaccination in cattle.
    Arch Virol. 2022 Jan 16. pii: 10.1007/s00705-021-05273.
    PubMed     Abstract available

    December 2021
  37. ZHAO W, Zhang P, Bai S, Lv M, et al
    Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice.
    Arch Virol. 2021;166:3333-3341.
    PubMed     Abstract available

    October 2021
  38. JANG Y, Seo SH
    H5 cleavage-site peptide vaccine protects chickens from lethal infection by highly pathogenic H5 avian influenza viruses.
    Arch Virol. 2021 Oct 25. pii: 10.1007/s00705-021-05284.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.